Literature DB >> 19228483

Aspirin resistance: an update.

Gilead I Lancaster1, Janardhan Srinivasan, Hitender Jain.   

Abstract

Aspirin resistance (AR) still lacks a universally accepted definition, but it may be discussed as either a laboratory phenomenon or a clinical presentation. Laboratory resistance is mainly defined as abnormal platelet response to aspirin, whereas the clinical manifestation is the failure of aspirin to prevent cardiovascular events. Although there is evidence of an association, it appears that a laboratory abnormality in platelet function is not the only risk factor for the clinical manifestation of AR. Therapies for primary and secondary prevention of AR still need to be elucidated, but there are some data to suggest that in an acute episode of aspirin failure because of AR, different therapeutic interventions need to be considered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19228483     DOI: 10.1007/s11883-009-0017-7

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  45 in total

1.  Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin.

Authors:  David C Sane; Scott A McKee; Alex I Malinin; Victor L Serebruany
Journal:  Am J Cardiol       Date:  2002-10-15       Impact factor: 2.778

2.  ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.

Authors:  Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; R Scott Wright; Sidney C Smith; Alice K Jacobs; Jonathan L Halperin; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  Circulation       Date:  2007-08-06       Impact factor: 29.690

Review 3.  Aspirin resistance: truth or dare.

Authors:  Marie Lordkipanidzé; Chantal Pharand; Donald A Palisaitis; Jean G Diodati
Journal:  Pharmacol Ther       Date:  2006-08-17       Impact factor: 12.310

4.  Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy.

Authors:  J H Alexander; R A Harrington; R H Tuttle; L G Berdan; A M Lincoff; J W Deckers; M L Simoons; A Guerci; J S Hochman; R G Wilcox; M M Kitt; P R Eisenberg; R M Califf; E J Topol; K Karsh; W Ruzyllo; J Stepinska; P Widimsky; J B Boland; P W Armstrong
Journal:  Am J Cardiol       Date:  1999-04-15       Impact factor: 2.778

5.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

6.  Low-dose aspirin increases aspirin resistance in patients with coronary artery disease.

Authors:  Pui-Yin Lee; Wai-Hong Chen; William Ng; Xi Cheng; Jeanette Yat-Yin Kwok; Hung-Fat Tse; Chu-Pak Lau
Journal:  Am J Med       Date:  2005-07       Impact factor: 4.965

7.  Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients.

Authors:  K H Grotemeyer; H W Scharafinski; I W Husstedt
Journal:  Thromb Res       Date:  1993-09-01       Impact factor: 3.944

8.  A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease.

Authors:  Marie Lordkipanidzé; Chantal Pharand; Erick Schampaert; Jacques Turgeon; Donald A Palisaitis; Jean G Diodati
Journal:  Eur Heart J       Date:  2007-06-14       Impact factor: 29.983

Review 9.  Optimizing platelet P2Y12 inhibition for patients undergoing PCI.

Authors:  Steven Steinhubl; Matthew T Roe
Journal:  Cardiovasc Drug Rev       Date:  2007

10.  A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.

Authors:  Patricia A Gum; Kandice Kottke-Marchant; Patricia A Welsh; Jennifer White; Eric J Topol
Journal:  J Am Coll Cardiol       Date:  2003-03-19       Impact factor: 24.094

View more
  2 in total

1.  ASA failure: does the combination ASA/clopidogrel confer better long-term vascular protection?

Authors:  Robert Côté; Yu Zhang; Robert G Hart; Leslie A McClure; David C Anderson; Robert L Talbert; Oscar R Benavente
Journal:  Neurology       Date:  2014-01-02       Impact factor: 9.910

2.  Clinical use of aspirin in treatment and prevention of cardiovascular disease.

Authors:  Yuxiang Dai; Junbo Ge
Journal:  Thrombosis       Date:  2011-11-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.